ArticleScientific reports2025
Phenotype disruption of umbilical cord derived MSC by cyclic mechanical stretch and hyperoxia mediated by p21.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Passage Numbers: How Culture Conditions and Population-Doubling Metrics Reporting Shape the Quality of Umbilical Cord-Derived MSCs and Extracellular Vesicles.International journal of molecular sciences · 2026Review
- Preventive application of lung growth factors and lack of attenuation of phenotype disruption of lung resident MSC from preterm infants by hyperoxia.Molecular and cellular pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preclinical studies provided convincing evidence that umbilical cord derived mesenchymal stem cells (UC-MSC) prevent lung injury and promote lung regeneration. We hypothesized that cyclic mechanical stretch (CMS) and hyperoxia (HOX) during mechanical ventilation account for their limited therapeutic efficacy within the clinics. UC-MSC cultures were subjected to CMS and HOX and evaluated for proliferation, cell viability and further functional properties. Reversibility of the phenotype changes was evaluated after recovery in room air following these exposures. CMS and HOX compromised cell viability and proliferation, altered phenotypic characteristics, particularly PDGFRα expression, and induced cellular senescence in UC-MSC. Effects were most pronounced for CMS plus HOX. The alterations of UC-MSC were mediated by p21 accumulation. As inhibition of p21 aggravated cell death of UC-MSC, the results indicated a cell defense mechanism to ensure survival. This assumption was underpinned by the principal reversibility of the phenotype alterations and regrowth after removal of CMS and HOX. But prolonged strongest exposures resulted in definite phenotype changes. CMS and HOX have comparable effects on UC-MSC as described for lung resident MSC. Our results explain their timely limited presence in the diseased lung after therapeutic application. Future research should therefore focus on their repetitive application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.